Search Cancer Clinical Trials

Mass General Brigham Cancer Institute offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
19 results
  • Cellular Therapy

2024P001014          Phase I

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Activity of Single Ascending Doses of SBT777101 in Subjects with Rheumatoid Arthritis

  • Ovarian Cancer, Cellular Therapy

24-570          Phase I

A Phase 1a/1b Study of 27T51, an anti-MUC16 CAR T cell drug product administered alone or in combination for participants with recurrent or refractory epithelial ovarian, primary peritoneal, or fallopian tube cancer

  • Cellular Therapy

24-317          Phase II

A Phase 2 trial of emapalumab for the prevention of CAR-T cell associated toxicities

  • Cellular Therapy, Multiple Myeloma

24-044          Phase II

A Phase 2, Open-Label, Multicenter Study of BMS-986393, a GPRC5D-directed CAR T Cell Therapy in Adult Participants with Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)

  • Lymphoma, Cellular Therapy

25-059          Phase II

A Phase 2, open-label, multicenter study of MB-105 in patients with CD5 positive (CD5+) relapsed / refractory T-cell lymphoma (r/r TCL)

  • Lymphoma, Cellular Therapy

20-011          Phase II

A Phase 2, Open-Label, Single-Arm, Multicohort, Multicenter Trial To Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL) (TRANSCEND FL)

  • Multiple Myeloma, Cellular Therapy

20-518          Phase I

A Phase I Clinical Trial with TriPRIL CAR T Cells for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

  • Lymphoma, Cellular Therapy

23-474          Phase I

A Phase I Study of Bivalent CD79b and CD19 Directed CAR T Cells in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

  • Cellular Therapy

2025P003179          Phase II

A Phase I/II Study of CC-97540 (BMS-986353), CD19-Targeted NEX-T CAR T Cells, in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitis

  • Cellular Therapy, Multiple Myeloma

25-319          Phase II

A Phase Ib/II Study of AZD0120, Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CAR T) Therapy Directed Against CD19 and B-cell Maturation Antigen (BCMA) in Participants With Relapsed/Refractory Multiple Myeloma DURGA-1

Showing 1 - 10 of 19 results